New vaccines are registered and marketed in Switzerland on the initiative of the pharmaceutical companies. Product registration is carried out by Swissmedic. It is independent of national recommendations for its use made by the Swiss Vaccination Commission. Financial support is then decided by the Federal Benefits Commission.
Currently, several new vaccines are thus registered and available on the market and are only recommended by the CSV for certain risk groups. In this situation therefore raises the question of accessibility to these vaccines and to information about them for all population Several vaccines will be developed and available in the coming years and this issue will be henceforth regularly raised. The task force for new vaccines therefore decided to develop an analytical framework that allows for an exhaustive and comprehensive assessment systematic of the factors that should be discussed before making a decision and recommend vaccination. Such work had already been done in Quebec and was made available to us. It has been taken up and adapted to the Swiss context. A series of key questions are set out and the elements that must be analyzed are detailed. The evaluation of a vaccine should be based on scientific evidence, using, if possible, a system of hierarchical classification of study validity. The analytical framework that is proposed can be used to serve as a basis for discussions within the Vaccination Commission or for procedures with the Federal Benefits Commission.
- Functioning
- Europe
- Switzerland
